Viatris takes the wheel as Cadillac F1 team's new global pharma partner

checkered flag finish line racecar
The official partnership begins in 2027, which will be Cadillac's second year in Formula 1. (Getty Images)

Another pharma is revving into the auto racing zone, this time with Viatris pulling up as the Cadillac Formula 1 team’s official global pharmaceutical partner. 

The multiyear partnership marries “motorsport and medicine, two industries where precision, reliability and performance matter,” Viatris said in a Nov. 16 press release, further connecting “two American companies with ambitious visions for the future.” 

"What attracted us to the Cadillac Formula 1 Team is the ambition and ingenuity behind what they're building," Viatris’ chief administrative and transformation officer Andrew Enrietti explained. "At Viatris, we're focused on executing our strategy and continuing to find ways to make a difference for patients around the world. We share a determination to embrace new opportunities, bring talented people and different perspectives together, and turn bold ideas into meaningful progress.” 

The overlaps between the two organizations continue as both “operate on a global scale and work on demanding timelines,” with the Cadillac F1 team moving “people, cars and equipment across continents," much like how Viatris brings its medicines to patients around the world. 

A 47-second promo video that goes along with the partnership features clips of Viatris’ work in the labs interspersed with action from the Cadillac F1 team, as a voiceover explains the companies have “different disciplines, shared ambition."

"Viatris makes medicines that people count on every day, and Formula 1 gives them one of the biggest stages in the world to show how they do it," Cadillac Formula 1 Team’s global head of commercial strategy, Tyler Epp, said in a statement, adding that the group is “thankful for the trust that Viatris has placed in our team."

Formula 1 is considered the world’s most prestigious motor racing competition and takes place on a large global stage, as opposed to U.S.-centric auto racing leagues such as NASCAR. Viatris will begin officially backing the Cadillac F1 team in 2027, which will be the newer team's second season in the series. 

The partnership allows Viatris to introduce itself to “new audiences around the world,” Enrietti added. 

The auto racing platform is one that many pharmas have leveraged recently in hopes of capturing some of the millions of viewers who tune into races each year. In 2026, nearly 3.7 million people attended Formula 1 race weekends in-person, according to the organization, while a five-year U.S. broadcasting partnership with Apple stands to expand the sport’s younger audience. 

Also hitting the grid is AbbVie, which recently signed a multiyear deal with the McLaren Formula 1 Team as an official pharmaceutical partner. AbbVie also launched its “Race to Innovate” campaign in tandem with the partnership, which looks to raise awareness of immune-mediated diseases and donate to global charities based on points McLaren earns.  

Meanwhile, on the NASCAR track, Boehringer Ingelheim teamed with race car driver Will Rodgers last month for the “Driving Good Health” program, a liver health awareness push that included a themed car and free non-invasive FibroScan liver assessments. 

Like the Cadillac Formula 1 Team, which debuted in 2026, Viatris is “entering a new phase of its evolution” six years after its 2020 founding. 

The company was formed as a drug powerhouse through the merger of Mylan and Pfizer’s Upjohn unit and has since been carving a path outside of its legacy products, most recently through a $1.65 billion buyout of Pacira BioSciences and its non-opioid pain therapies. Earlier this year, Viatris announced a three-year-long strategic restructuring that will cut 10% of its workforce in a bid to save up to $700 million annually. Last year, the company pulled annual revenues of $14.3 billion.